Patients experiencing inadequate appetite suppression after reaching maintenance doses should undergo comprehensive evaluation for factors that may impair treatment response, including medication interactions, adherence issues, or underlying medical conditions requiring additional intervention
Here is what matters and what does not
Please continue reading to learn more about some of the safety concerns associated with semaglutide use
No bowel movement for 7+ days
Novo Nordisk has petitioned the FDA to add semaglutide to the Demonstrable Difficulties for Compounding (DDC) list, which would further restrict compounding
Whether pursuing GLP-1 medications, bariatric procedures, or structured weight loss programs, upfront costs can delay care for months or even years